Taro Pharmaceutical Launches AB-Rated Lamotrigine ODT Generics Across Four Strengths

Formulary substitution decisions for Lamictal ODT now have a new reference point: Taro Pharmaceutical Industries has entered the lamotrigine orally disintegrating tablet market with an AB-rated generic across all four commercially relevant strengths, 25 mg, 50 mg, 100 mg, and 200 mg.

The AB therapeutic equivalence rating, assigned under 21 CFR Part 314 bioequivalence standards, confirms substitutability with the branded reference listed drug, Lamictal ODT. For pharmacy and formulary teams, that rating is the operative signal: automatic substitution is permissible where state law allows, and payer-driven step edits can now route to Taro's NDCs without additional clinical review.

Each strength is packaged in 30-tablet counts under NDC codes 51672-4252-6 through 51672-4255-6. The tablet description, white to off-white, is consistent across the line, a detail relevant to patient counseling and unit-dose repackaging operations where visual differentiation between strengths depends on labeling rather than appearance.

For manufacturers and CMOs tracking ODT platform adoption, Taro's full-strength launch reflects the continued commercial viability of orally disintegrating formats in the CNS generic space. ODT manufacturing carries distinct process validation requirements relative to conventional oral solids, friability thresholds, disintegration time specifications, and humidity-controlled packaging lines each represent GMP control points that differentiate ODT-capable facilities from standard tablet operations.

The lamotrigine ODT category serves patients managing epilepsy and bipolar disorder, populations where dosing consistency and adherence formulation matter clinically. Increased generic competition across all four strengths simultaneously, rather than a phased entry, compresses the window during which any single generic holds preferred formulary position.

Taro's ability to sustain supply across the full strength range will be a measurable indicator of its ODT manufacturing capacity over the next formulary review cycle.

Source: Taro Pharmaceutical Industries via taro.com, June 15, 2026.